别名B cell CLL/lymphoma 7 protein family member C; B cell CLL/lymphoma 7C; B-cell CLL/lymphoma 7 protein family member C; BCL 7C; Bcl7c; BCL7C_HUMAN. 英文名称 Anti-BCL7C 中文名称 B细胞白血病/淋巴瘤蛋白7抗体 浓度1mg/1ml 规格0.2
别名B cell CLL/lymphoma 7 protein family member C; B cell CLL/lymphoma 7C; B-cell CLL/lymphoma 7 protein family member C; BCL 7C; Bcl7c; BCL7C_HUMAN. 浓度1mg/1ml 规格0.2ml/200μg 抗体来源 Rabbit 克隆类型 polyclonal 交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow 产品类型 ...
BCL7B is called B-cell CLL/lymphoma 7 protein family member B. The protein encoded by BCL7B gene is a BAF-type specific subunit of SWI/SNF. From:Current Topics in Membranes,2021 About this page Set alert Medicine and Dentistry Chapters and Articles ...
cell signature genes is maintained in some lymphoma cell lines26, which indicates that this signature is a stable change in gene expression and does not require the cellular interactions that are present in the GC microenvironment to be maintained. So, the GC B cell is at a discrete stage of...
BCL7B (B Cell CLL/Lymphoma 7 Protein Family Member B) Basic information More.. Product Name: BCL7B (B Cell CLL/Lymphoma 7 Protein Family Member B) Synonyms: BCL7B (B Cell CLL/Lymphoma 7 Protein Family Member B) CAS: MF: MW: 0 EINECS: Mol File: Mol File Information Error ...
In this review, we focus on two types of B cell malignancy: indolent Chronic Lymphocytic Leukemia (CLL) and aggressive Diffuse Large B-Cell Lymphoma (DLBCL). CLL is the most common B-cell malignancy in adults and it is characterized by an accumulation of CD5+ monoclonal mature B lymphocytes...
Prognostic efficacy of theRTN1gene in patients with diffuse large B-cell lymphoma ArticleOpen access26 October 2021 Introduction Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in Western countries1. While generally considered an indolent B cell disease, CLL is in fact associated wit...
Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primar
GB activates the proapoptotic B cell CLL/lymphoma 2 (Bcl-2) family member BH3-interacting domain death agonist (BID) to switch on the intrinsic mitochondrial death pathway, leading to Bcl-2-associated X protein (Bax)/Bcl-2 homologous antagonist/killer- (Bak-) dependen...
Background Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Although most patients can be cured with R-CHOP, up to one-third of them relapses with a dismal outcome in most cases. Numerous approaches ...